Thus, for all of the macrophage subtypes found in the TME of DLBCL, SLAMF7 expression on cancer cells is not required for anticancer activity upon CD47 targeting, with M2 macrophages appearing to respond more effectively to CD47-targeting than M1 macrophages while having lower SLAMF7 expression (Supplementary Figure 1B, C). The gene discussed is SLAMF7; the disease is diffuse large B-cell lymphoma.